Literature DB >> 34101497

Paving the Way for Long-Term Survival in Non-Small-Cell Lung Cancer.

Jordi Remon1, Lizza E L Hendriks2, Benjamin Besse3,4.   

Abstract

Entities:  

Year:  2021        PMID： 34101497     DOI： 10.1200/JCO.21.00760

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  2 in total

1.  Association between the baseline tumor size and outcomes of patients with non-small cell lung cancer treated with first-line immune checkpoint inhibitor monotherapy or in combination with chemotherapy.

Authors:  Yuji Uehara; Taiki Hakozaki; Rui Kitadai; Kosuke Narita; Kageaki Watanabe; Kana Hashimoto; Shoko Kawai; Makiko Yomota; Yukio Hosomi
Journal:  Transl Lung Cancer Res       Date:  2022-02

Review 2.  Navigate Towards the Immunotherapy Era: Value of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer Patients With Brain Metastases.

Authors:  Guanqun Yang; Ligang Xing; Xiaorong Sun
Journal:  Front Immunol       Date:  2022-03-29       Impact factor: 7.561
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.